Prostate cancer: Mixed responses to ipilimumab

Nature Reviews Urology

Volumn 11, Issue 6, 2014, Pages 305-

  Killock, David ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

IPILIMUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; TAXOID;

CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; DRUG RESPONSE; HUMAN; NOTE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; MALE; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; HUMANS; MALE; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; TAXOIDS;

EID: 84902550794     PISSN: 17594812     EISSN: 17594820     Source Type: Journal    
DOI: 10.1038/nrurol.2014.121     Document Type: Note

References (1)

1. Kwon, E. D. et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. doi:10.1016/S1470-2045(14)70189-5